Efficacy and Safety of Omalizumab in Chinese Pediatric Patients Under 12 with Chronic Urticaria: A Case Series Analysis - Takeaways - MDSpire

Efficacy and Safety of Omalizumab in Chinese Pediatric Patients Under 12 with Chronic Urticaria: A Case Series Analysis

  • By

  • Hui Zhao

  • Lei Luo

  • Wan-Ming Jia

  • April 21, 2026

  • 0 min

Share

  • 1

    Omalizumab effectively treats chronic urticaria in children under 12, with all 13 patients showing rapid improvement within one week.

  • 2

    The median Urticaria Activity Score decreased significantly from 20.0 at baseline to 4.0 after four weeks of omalizumab treatment.

  • 3

    All patients successfully discontinued oral antihistamines within four weeks, indicating strong therapeutic response to omalizumab.

  • 4

    No adverse events were reported during the study, highlighting the excellent safety profile of omalizumab in this pediatric cohort.

  • 5

    Nearly half of the patients had comorbid allergic conditions, suggesting a complex clinical profile among children with chronic urticaria.

Original Source(s)

Efficacy and Safety of Omalizumab in Chinese Pediatric Patients Under 12 with Chronic Urticaria: A Case Series Analysis

  • by Hui Zhao, Lei Luo, Wan-Ming Jia

  • April 21, 2026

Related Content

Medical Oddities: Can a Home Be Preventive Care?

This week’s medical plot twists involved ants, architecture, and auditory hallucinations.

Restraint care in the pediatric intensive care unit: a qualitative investigation of nurses’ perspectives and experiences

Giant rapidly involuting congenital hemangioma in a neonate: a case report